ESMO 2018 CONGRESS October 2018 Munich, Germany. Developed in association with the European Thoracic Oncology Platform
|
|
- Rosalyn Eaton
- 5 years ago
- Views:
Transcription
1 Developed in association with the European Thoracic Oncology Platform ESMO 218 CONGRESS October 218 Munich, Germany Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this publication
2 Letter from Prof Rolf Stahel Dear Colleagues It is my pleasure to present this ETOP slide set which has been designed to highlight and summarise key findings in thoracic cancers from the major congresses in 218. This slide set specifically focuses on the ESMO 218 Congress and is available in 4 languages English, French, Chinese and Japanese. The area of clinical research in oncology is a challenging and ever changing environment. Within this environment, we all value access to scientific data and research which helps to educate and inspire further advancements in our roles as scientists, clinicians and educators. I hope you find this review of the latest developments in thoracic cancers of benefit to you in your practice. If you would like to share your thoughts with us we would welcome your comments. Please send any correspondence to etop@etop.eu-org. I would like to thank our ETOP members Solange Peters and Martin Reck for their roles as Editors for prioritising abstracts and reviewing slide content. The slide set you see before you would not be possible without their commitment and hard work. Finally, we are also very grateful to Lilly Oncology for their financial, administrative and logistical support in the realisation of this activity. Yours sincerely, Rolf Stahel President, ETOP Foundation Council
3 ETOP Medical Oncology Slide Deck Editors 218 Focus: advanced NSCLC (not radically treatable stage III & stage IV) Dr Solange Peters Multidisciplinary Oncology Center, Lausanne Cancer Center, Lausanne, Switzerland Focus: other malignancies, SCLC, mesothelioma, rare tumours Dr Martin Reck Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
4 Contents Screening and biomarkers Early stage and locally advanced NSCLC Stages I, II and III Advanced NSCLC Not radically treatable stage III and stage IV First line Later lines Other malignancies SCLC, mesothelioma and thymic epithelial tumours
5 Screening and biomarkers
6 65PD: High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-pd-l1 and anti-ctla-4 Higgs BW, et al Study objective To compare the utility of high TMB and PD-L1 to predict outcomes in patients with non-squamous NSCLC who were treated with durvalumab and tremelimumab Methods Immunotherapy-naïve patients (n=213) with non-squamous EGFR and ALK wildtype NSCLC who had progressed after one prior platinum-based therapy were enrolled to durvalumab 2 mg/kg q4w for up to 12 months with tremelimumab 1 mg/kg q4w for 4 cycles Tumour PD-L1 expression classified as 25% or <25% using the Ventana PD-L1 (SP263) assay DNA sequencing was performed on 16 of 2 (53%) available tumour biopsies and TMB high defined as the top tertile of values (11 mut/mb) Higgs BW, et al. Ann Oncol 218;29(suppl 5):Abstr 65PD
7 PD-L1 TC, % 65PD: High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-pd-l1 and anti-ctla-4 Higgs BW, et al Key results There was no appreciable correlation between TMB and PD-L1 Low linear correlation between PD-L1 levels and TMB PD-L1 vs. TMB status overlap TMB, mutations/mb rho= PD-L1 25% n=16 16% n=18 17% PD-L1 <25%/ TMB low n=52 5% TMB high n=17 17% Higgs BW, et al. Ann Oncol 218;29(suppl 5):Abstr 65PD
8 65PD: High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-pd-l1 and anti-ctla-4 Higgs BW, et al Key results PFS Conclusions TMB 11 mut/mb (n=37) TMB <11 mut/mb (n=69) PD-L1 25% (n=57) PD-L1 <25% (n=136) Total* (N=213) Median, months (95%CI) 7.1 (1.7, 9.1) 1.7 (1.6, 3.6) 7.1 (3.5, 9.2) 3.3 (1.7, 3.6) 3.5 (1.8, 4.) 12-month PFS, % (95%CI) 26.8 (13.8, 41.6) 12.6 (5.6, 22.6) 34.2 (21.9, 46.8) 1. (4.8, 17.5) 17.6 (12.4, 23.6) OS Median, months (95%CI) NE (7.9, NE) 8.9 (4.8, NE) 15.5 (15.4, NE) 9.5 (6.7, NE) 15.4 (1., NE) 12-month OS, % (95%CI) 61.2 (42.4, 75.5) 43. (3.4, 55.) 71.6 (57.3, 81.9) 47.3 (38.2, 55.9) 53.8 (46.4, 6.6) *2 patients had unknown PD-L1 expression; NE, not estimable In this study of patients with non-squamous NSCLC TMB and PD-L1 expression were not correlated Patients who were TMB high ( 11 mut/mb) had improved ORR, PFS and OS Higgs BW, et al. Ann Oncol 218;29(suppl 5):Abstr 65PD
9 LM15 LM18 LM21 LM14 LM1 LM8 LM13 LM16 LM11 LM19 BM12 BM14 BM18 BM15 Neoantigen counts 1136PD: Discrepancy of tumor neoantigen burden between primary lesions and matched metastases in lung cancer Jiang T, et al Study objective To compare neoantigen landscapes in primary tumours and metastases in patients with lung cancer Key result Comparison of neoantigens in primary tumours and metastases by baseline characteristics Gender Smoking Histology Primary Female Yes SCLC Metastasis Male No LUAD LUSC 4 Age, years Gender Smoking Histology Conclusion Neoantigen landscapes were similar in primary tumours and metastases, however, only 2% of neoantigens were shared Jiang T, et al. Ann Oncol 218;29(suppl 5):Abstr 1136PD
10 Early stage and locally advanced NSCLC Stages I, II and III
11 LBA48_PR: CTONG 113: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment for stage IIIA N2 EGFR-mutation non-small-cell lung cancer (EMERGING): a randomised study Zhong W, et al Study objective To investigate the efficacy of erlotinib vs. gemcitabine + cisplatin as neoadjuvant/ adjuvant treatment in patients with locally advanced EGFR mutant NSCLC Key patient inclusion criteria Treatment naïve IIIA-N2 NSCLC EGFR activating mutation ECOG PS 1 (n=72) R 1:1 Erlotinib 15 mg/day for 42 days (n=37) Stratification Lymph node status Histology Smoking Sex Gemcitabine + cisplatin* q3w for 2 cycles (n=35) Non-PD S U R G E R Y Erlotinib 15 mg/day for 12 months Gemcitabine + cisplatin* q3w for 2 cycles Primary endpoint ORR *Gemcitabine 125 mg/m 2 D1, 8; cisplatin 75 mg/m 2 D1 Secondary endpoints Downstaging rates of pathological lymph nodes, pcr, PFS, OS, safety Zhong W, et al. Ann Oncol 218;29(suppl 5):Abstr LBA48_PR
12 LBA48_PR: CTONG 113: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment for stage IIIA N2 EGFR-mutation non-small-cell lung cancer (EMERGING): a randomised study Zhong W, et al Key results ORR in the ITT population was 54.1% (95%CI 37.2, 7.9) with erlotinib vs. 34.3% (95%CI 17.7, 5.8) with gemcitabine + cisplatin (OR 2.26 [95%CI.87, 5.84], p=.92) Erlotinib (n=37) Gemcitabine + cisplatin (n=35) p-value Surgery, n (%) 31 (83.8) 24 (68.6).129 Complete resection, n (%) R R1 R2 Lymph node downstage, n (%) N2 pn N2 pn1 N2 pn2 27 (73.) 27 (73.) 1 (2.7) 3 (8.1) 4 (1.8) 3 (8.1) 1 (2.7) 27 (73.) 22 (62.9) 22 (62.9) 1 (2.9) 1 (2.9) 1 (2.9) 1 (2.9) () 23 (65.7) Zhong W, et al. Ann Oncol 218;29(suppl 5):Abstr LBA48_PR
13 Progression-free survival, % LBA48_PR: CTONG 113: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment for stage IIIA N2 EGFR-mutation non-small-cell lung cancer (EMERGING): a randomised study Zhong W, et al Key results % PFS (ITT population) Group Events mpfs, months (95%CI) No.at risk Erlotinib Gemcitabine + cisplatin Conclusion 49.% 36.4% % Time, months Erlotinib in the neoadjuvant setting for EGFRm NSCLC improved ORR, MPR, R resection and lymph node downstaging and the safety profile was in line with previous reports Zhong W, et al. Ann Oncol 218;29(suppl 5):Abstr LBA48_PR 42 Erlotinib (n=37) (19.3, 23.6) Gemcitabine + cisplatin (n=35) (9.1, 14.7) HR.42 (95%CI.23,.76), p=.3
14 LBA49: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC) Cascone T, et al Study objective To investigate the efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with untreated resectable NSCLC Key patient inclusion criteria Nivolumab 3 mg/kg D 1, 15, 29 (n=18) Surgery Adjuvant therapy Stage I IIIA NSCLC Eligible for surgery R 1:1 Stratification Stage (n=44) Ipilimumab 1 mg/kg D1 + nivolumab 3 mg/kg D1, 15, 29 (n=18) Surgery Adjuvant therapy Primary endpoint Major pathological response (MPR) Secondary endpoints Safety, perioperative mortality and morbidity, ORR, RFS, OS, complete resection rate, pcr Cascone T, et al. Ann Oncol 218;29(suppl 5):Abstr LBA49
15 LBA49: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC) Cascone T, et al Key results Total Nivolumab Nivolumab + ipilimumab Evaluable (resected) n=26 n=14 n=12 MPR + pcr, n (%) 8 (31) 4 (28) 4 (33) % viable tumour cells (pcr), n (%) 5 (19) 2 (14) 3 (25) 1 1% viable tumour cells, n (%) 3 (11) 2 (14) 1 (8) Overall (resected + unresectable) n=31 n=16 n=15 MPR + pcr, n (%) 8 (26) 4 (25) 4 (27) % viable tumour cells (pcr), n (%) 5 (16) 2 (13) 3 (2) 1 1% viable tumour cells, n (%) 3 (1) 2 (13) 1 (7) Cascone T, et al. Ann Oncol 218;29(suppl 5):Abstr LBA49
16 Overall % change in tumour size from baseline LBA49: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC) Cascone T, et al Key results (cont.) Evaluable Response, n (%) CR PR SD PD ORR, n/n (%) Total (n=32) 1 (3) 6 (19) 19 (59) 6 (19) 7/32 (22) Nivolumab (n=16) () 5 (31) 8 (5) 3 (19) 5/16 (31) Nivolumab + ipilimumab (n=16) 1 (6) 1 (6) 11 (69) 3 (19) 2/16 (12) * Nivolumab (evaluable) (n=16) Radiographic responses 2 12 * Nivolumab + ipilimumab (evaluable) (n=16) * *Considered SD in target lesion but overall PD due to new radiographic lesions * 1 Conclusions In resected patients with NSCLC, neoadjuvant nivolumab or nivolumab + ipilimumab induced an MPR rate of 31% Greater TIL proliferation and activation was demonstrated with neoadjuvant nivolumab and nivolumab + ipilimumab compared with untreated tumours Cascone T, et al. Ann Oncol 218;29(suppl 5):Abstr LBA49
17 1363O: Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC Faivre-Finn C, et al Study objective To investigate the efficacy and safety outcomes of durvalumab in the PACIFIC trial based on PD-L1 expression and the components of chemoradiation received prior to durvalumab or placebo Key patient inclusion criteria Stage III NSCLC No progression after 2 cycles of platinum-crt Pre-cCRT tumour tissue for PD-L1 testing if available WHO PS 1 (n=713) R 1:1 Durvalumab 1 mg/kg q2w (n=476) Stratification Age Sex Smoking history Placebo q2w (n=237) Primary endpoints PFS by BICR, OS Secondary endpoints ORR, DoR and TTDM by BICR, PFS2 by investigator, safety, PROs Faivre-Finn C, et al. Ann Oncol 218;29(suppl 5):Abstr 1363O
18 Probability of PFS Probability of PFS 1363O: Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC Faivre-Finn C, et al Key results 1. PFS (BICR) by PD-L1 TC 1% PFS (BICR) by PD-L1 TC <1% Events/ patients (%) Median PFS, months (95%CI) Durvalumab 84/212 (39.6) 17.8 (16.9, NR) Placebo 59/91 (64.8) 5.6 (3.6, 11.) HR.46 (95%CI.33,.64) 1. Events/ patients (%) Median PFS, months (95%CI) Durvalumab 49/9 (54.4) 1.7 (7.3, NR) Placebo 4/58 (69.) 5.6 (3.7, 1.6) HR.73 (95%CI.48, 1.11) No. at risk Durvalumab Placebo Time from randomisation, months No. at risk Durvalumab Placebo Time from randomisation, months Median OS in the PD-L1 TC 1% was NR (95%CI NR, NR) with durvalumab and 29.1 months (95%CI 17.7, NR) for placebo; HR.53 (95%CI.36,.77) Median OS in the PD-L1 TC <1% was NR (95%CI 2.8, NR) with durvalumab and NR (95%CI 27.3, NR) for placebo; HR 1.36 (95%CI.79, 2.34) Faivre-Finn C, et al. Ann Oncol 218;29(suppl 5):Abstr 1363O
19 1363O: Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC Faivre-Finn C, et al Key results (cont.) Induction chemotherapy Platinum Taxane Etoposide Vinorelbine Dose of radiotherapy Yes No Cisplatin Carboplatin Yes No Yes No Yes No <6 Gy 6 66 Gy >66 Gy PFS (BICR) Events / patients (%) HR (95%CI) Durvalumab Placebo /123 (48.) 155/353 (43.9) 115/266 (43.2) 91/199 (45.7) 97/27 (46.9) 117/269 (43.5) 49/117 (41.9) 165/359 (46.) 58/124 (46.8) 156/352 (44.3) 16/38 (42.1) 187/47 (45.9) 1/3 (33.3) 49/68 (72.1) 18/169 (63.9) 87/129 (67.4) 65/12 (63.7) 72/112 (64.3) 85/125 (68.) 34/52 (65.4) 123/185 (66.5) 42/59 (71.2) 115/178 (64.6) 11/15 (73.3) 13/22 (64.4) 15/19 (78.9) Conclusions Durvalumab better Placebo better Durvalumab led to improvement in PFS and OS in the PD-L1 1% subgroup and PFS in the <1% PD-L1 subgroup Durvalumab improved PFS and OS regardless of chemoradiation received prior to therapy Faivre-Finn C, et al. Ann Oncol 218;29(suppl 5):Abstr 1363O
20 Advanced NSCLC Not radically treatable stage III and stage IV First line
21 LBA1: Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC Zhou C, et al Study objective To investigate safety and efficacy of 1L alectinib vs. crizotinib in Asian patients with ALK+ NSCLC in the ALESIA study Key patient inclusion criteria Asian patients with stage IIIB/IV ALK+ NSCLC Treatment naïve ECOG PS 2 (n=187) R 2:1 Alectinib 6 mg bid (n=125) Stratification ECOG PS (/1 vs. 2) Baseline brain metastases Crizotinib 25 mg bid (n=62) Primary endpoint PFS (investigator-assessed) Secondary endpoints PFS by IRC, time to CNS progression, ORR and DoR (investigator-assessed), OS, CNS ORR, safety, QoL, PK Zhou C, et al. Ann Oncol 218;29(suppl 5):Abstr LBA1
22 Progression-free survival, % Cumulative incidence*, % LBA1: Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC Zhou C, et al Key result PFS (investigator-assessed) Time to CNS progression (IRC-assessed) 1 Alectinib Crizotinib 6 Alectinib Crizotinib NE % (95%CI 23.5, 47.8) months Time, months 7.3% (95%CI 3.6, 12.8) Time, months Alectinib (n=125) Crizotinib (n=62) Patients with event, n (%) 26 (2.8) 37 (59.7) Median PFS, months (95%CI) NE (2.3, NE) 11.1 (9.1, 13.) HR (95%CI); p-value (log-rank test).22 (.13,.38); <.1 Cause-specific HR p-value (log-rank test).14 (95%CI.6,.3) <.1 *Cumulative incidence of CNS progression without prior non-cns progression or death Zhou C, et al. Ann Oncol 218;29(suppl 5):Abstr LBA1
23 DoR (unconfirmed),% LBA1: Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC Zhou C, et al Key result (cont.) Alectinib Crizotinib months Time, months Alectinib (n=114) NE Crizotinib (n=48) Median DoR, months (95%CI) NE (18.4, NE) 9.3 (7.4, NE) HR (95%CI), p-value (log-rank test) DoR (investigator-assessed).22 (.12,.4); p<.1 Response, n (%) Alectinib (n=125) Crizotinib (n=62) ORR 114 (91.2) 48 (77.4) CR 5 (4.) 3 (4.8) PR 19 (87.2) 45 (72.6) SD 7 (5.6) 8 (12.9) PD 2 (1.6) 4 (6.5) Missing or unevaluable 2 (1.6) 2 (3.2) Conclusions Alectinib led to a significant improvement in PFS and showed benefits in regards to ORR, DoR and time to CNS progression compared with crizotinib The safety profile of alectinib in Asian patients was consistent with the previous findings Zhou C, et al. Ann Oncol 218;29(suppl 5):Abstr LBA1
24 LBA5: Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study Ramalingam SS, et al Study objective To investigate the mechanisms of acquired resistance to osimertinib and standard of care (gefitinib + erlotinib) in patients who progressed or discontinued treatment in the FLAURA study Methods Patients in the FLAURA study had EGFR+ (ex19del or L858R) locally advanced or metastatic NSCLC and were treated with osimertinib or gefitinib + erlotinib until progression Paired plasma samples were taken from patients at baseline and at progression/discontinuation for ctdna genomic profiling NGS was conducted using the Guardant36 assay or GuardantOMNI assay Analysis set of valid paired NGS data were available for 272 patients Osimertinib: 113/279 (41%) Gefitinib + erlotinib: 159/277 (57%) Ramalingam SS, et al. Ann Oncol 218;29(suppl 5):Abstr LBA5
25 LBA5: Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study Ramalingam SS, et al Key results The most common acquired resistance mechanisms in the osimertinib arm (n=91) were: MET amplification (15%) and EGFR C797S mutation (7%) There was no evidence of acquired T79M The most common acquired resistance mechanisms in the gefitinib + erlotinib arm (n=129) were: T79M (47%), MET amplification (4%) and HER2 amplification (2%) Conclusions There was no evidence of acquired resistance through T79M in the osimertinib-treated patients, while MET amplification and EGFR C797S mutations were the most common New mechanisms that may lead to aggressive disease biology were not identified Ramalingam SS, et al. Ann Oncol 218;29(suppl 5):Abstr LBA5
26 LBA51: Analysis of resistance mechanisms to osimertinib in patients with EGFR T79M advanced NSCLC from the AURA3 study Papadimitrakopoulou VA, et al Study objective To investigate the mechanisms of acquired resistance to osimertinib in patients who progressed or discontinued treatment in the AURA3 study Methods Patients in the AURA3 study had T79M+ locally advanced or metastatic NSCLC and were treated with osimertinib or platinum-pemetrexed until progression Paired plasma samples were taken from patients at baseline and at progression/discontinuation for ctdna genomic profiling NGS was undertaken using the Guardant36 assay Analysis set of valid paired NGS data were available for 113 patients Osimertinib: 83/279 (3%) Platinum-pemetrexed: 3/14 (21%) Papadimitrakopoulou VA, et al. Ann Oncol 218;29(suppl 5):Abstr LBA51
27 LBA51: Analysis of resistance mechanisms to osimertinib in patients with EGFR T79M advanced NSCLC from the AURA3 study Papadimitrakopoulou VA, et al Key results Loss of T79M was seen in 49% of patients Acquired EGFR mutations were observed in 21% of patients; the most common was C797S (14%) Other mutations included: MET amplification (19%); cell cycle gene alterations (12%); HER2 amplification (5%); PIK3CA amplification/mutation (5%); oncogenic fusion (4%), BRAF V6E (3%) All cases of C797X mutations were in the cis position when co-occurring with T79M Conclusion Acquired EGFR mutations with osimertinib (represents 21% of total patients) C797X: 15% (1 C797S, 1 C797G) L792H/F + C797S: 1% L792H: 1% G796S: 1% L718Q: 1% Ex2ins: 1% EGFR mutations and MET amplifications were the most common acquired resistance mechanisms to osimertinib among a diverse mixture, consistent with previous reports Papadimitrakopoulou VA, et al. Ann Oncol 218;29(suppl 5):Abstr LBA51
28 LBA52: Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC28) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC) Wolf J, et al Study objective To investigate the efficacy and safety of capmatinib, a selective MET inhibitor, in patients with METΔex14 mutated advanced NSCLC Key patient inclusion criteria Stage IIIB/IV NSCLC METΔex14 determined centrally EGFR wt and ALK negative 1 measureable lesion ECOG PS 1 Cohort 4: Previously treated (1 2 prior lines) for advanced stage Capmatinib 4 mg bid (n=69) Cohort 5b: Treatment-naïve for advanced stage Capmatinib 4 mg bid (n=28) Primary endpoint ORR by BIRC Secondary endpoints DoR by BIRC Wolf J, et al. Ann Oncol 218;29(suppl 5):Abstr LBA52
29 Best % change from baseline Best % change from baseline LBA52: Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC28) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC) Wolf J, et al Key results ORR (BIRC) in Cohort 4 (pre-treated) was 39.1% (95%CI 27.6, 51.6) ORR (BIRC) in Cohort 5b (treatment naïve) was 72.% (95%CI 5.6, 87.9) 25 Cohort 4 (pre-treated) * n=6 /69 * * * Cohort 5b (treatment naïve) * * * * * * * * * 25 * 5 75 * * * * * * n=24 /25 PR SD PD NE * * * * 1 *Patients still on treatment; number of patients with measurable disease at baseline and 1 post-baseline assessment Wolf J, et al. Ann Oncol 218;29(suppl 5):Abstr LBA52
30 LBA52: Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC28) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC) Wolf J, et al Key results AE, n (%) Conclusions Cohort 4 (pre-treated) (n=69) Cohort 5b (treatment naive) (n=28) All patients (N=32) All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 Any 6 (87.) 33 (47.8) 27 (96.4) 14 (5.) 253 (83.8) 1 (33.1) Peripheral oedema 31 (44.9) 1 (14.5) 18 (64.3) 1 (3.6) 122 (4.4) 19 (6.3) Nausea 24 (34.8) 11 (39.3) 99 (32.8) 5 (1.7) Vomiting 13 (18.8) 4 (14.3) 58 (19.2) 6 (2.) Blood creatinine increased 15 (21.7) 7 (25.) 58 (19.2) Fatigue 9 (13.) 4 (5.8) 2 (7.1) 1 (3.6) 4 (13.2) 1 (3.3) Decreased appetite 1 (14.5) 1 (1.4) 5 (17.9) 4 (13.2) 3 (1.) Diarrhoea 8 (11.6) 3 (1.7) 35 (11.6) In patients with METΔex14 advanced NSCLC, capmatinib shows promising results The differential benefit of 1L over later-line treatment highlights the need for prompt targeted treatment in this patient group Wolf J, et al. Ann Oncol 218;29(suppl 5):Abstr LBA52
31 LBA53: IMpower13: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Cappuzzo F, et al Study objective To investigate the efficacy and safety of atezolizumab combined with carboplatin + nab-paclitaxel vs. carboplatin + nab-paclitaxel in chemotherapy-naïve patients with stage IV non-squamous NSCLC Key patient inclusion criteria Stage IV nonsquamous NSCLC Chemotherapy-naïve Pre-treated EGFR mutated or ALK translocation (TKI) (n=723; ITT-WT* n=679) R 2:1 Induction treatment (4 or 6 cycles) Atezolizumab 12 mg q3w + carboplatin AUC 6 q3w + nab-paclitaxel 1 mg/m 2 q3w Stratification Sex Baseline liver metastases PD-L1 tumour expression Carboplatin AUC 6 q3w + nab-paclitaxel 1 mg/m 2 q3w Maintenance treatment Atezolizumab Best supportive care or pemetrexed q3w Loss of clinical benefit/ toxicity PD/ toxicity Co-primary endpoints Investigator-assessed PFS and OS (ITT-WT* population) *ITT-WT population, randomised patients excluding those with EGFR or ALK mutations Secondary endpoints OS and PFS (ITT population and by PD-L1 expression), ORR, safety Cappuzzo F, et al. Ann Oncol 218;29(suppl 5):Abstr LBA53
32 PFS, % LBA53: IMpower13: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Cappuzzo F, et al OS, % Key results Investigator-assessed PFS (ITT-WT) OS (ITT-WT) PFS rate, % 6-month 12-month.8 OS rate, % 1-year 2-year Atezolizumab + CnP Atezolizumab + CnP CnP CnP Median follow-up: ~19 months HR.64 (95%CI.54,.77) p<.1.4 HR.79 (95%CI.64,.98) p= Median: 5.5 mo (95%CI 4.4, 5.9) Median: 7. mo (95%CI 6.2, 7.3). Median: 13.9 mo (95%CI 12., 18.7) Median: 18.6 mo (95%CI 16., 21.2) No. at risk Atezo + CnP Chemo Months after randomisation No. at risk Atezo + CnP Chemo Months after randomisation Cappuzzo F, et al. Ann Oncol 218;29(suppl 5):Abstr LBA53
33 LBA53: IMpower13: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Cappuzzo F, et al PFS, % PFS, % PFS, % Key results (cont.) 1 8 PD-L1-high TC3 or IC3 PFS by baseline PD-L1 status (ITT-WT) 1 8 PD-L1-low TC1/2 or IC1/2 1 8 PD-L1-negative TC and IC No. at risk Atezo+CnP Chemo Time, months Time, months Time, months Median PFS, mo (95%CI) Conclusions Atezo + CnP (n=88) 6.4 (5.49, 9.76) HR (95%CI).51 (.34,.77) CnP (n=42) 4.6 (3.22, 7) Median PFS, mo (95%CI) Atezo + CnP (n=128) 8.3 (7.16, 1.35) HR (95%CI).61 (.43,.85) In the ITT-WT population atezolizumab + chemotherapy showed benefit in PFS and OS, which was maintained across all PD-L1 subgroups No new safety signals were observed with the combination of atezolizumab + chemotherapy Cappuzzo F, et al. Ann Oncol 218;29(suppl 5):Abstr LBA53 CnP (n=65) 6. (5.29, 6.93) Median PFS, mo (95%CI) Atezo + CnP (n=235) 6.2 (5.52, 7.16) HR (95%CI).72 (.56,.91) CnP (n=121) 4.7 (4.11, 5.72)
34 LBA54: IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) Barlesi F, et al Study objective To investigate the PFS benefit of atezolizumab combined with carboplatin or cisplatin + pemetrexed in patients from IMpower132 in an exploratory analysis stratified by race, age, smoking history or liver metastasis at baseline Key patient inclusion criteria Stage IV nonsquamous NSCLC Chemotherapy-naïve Without EGFR or ALK genetic alteration Exploratory endpoints R 1:1 Clinical and biomarker subgroup analysis Induction therapy (4 or 6 cycles) Atezolizumab + carboplatin or cisplatin + pemetrexed* Stratification Sex Smoking status ECOG PS Chemotherapy regimen (n=578) Carboplatin or cisplatin + pemetrexed* Maintenance therapy Atezolizumab + pemetrexed* Pemetrexed* PD/ loss of clinical benefit PD/ loss of clinical benefit *Atezolizumab 12 mg IV q3w; carboplatin AUC 6 mg/ml/min IV q3w; cisplatin 75 mg/m 2 IV q3w; pemetrexed 5 mg/m 2 IV q3w Barlesi F, et al. Ann Oncol 218;29(suppl 5):Abstr LBA54
35 PFS, % PFS, % PFS, % PFS, % LBA54: IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) Barlesi F, et al Key results 1. Median PFS (95%CI), mos HR (95%CI) Non-Asian patients Atezolizumab + PP PP 6.9 (5.9, 8.1) 5. (4.2, 5.7).65 (.53,.81) Median PFS (95%CI), mos HR (95%CI) 1. Asian patients Atezolizumab + PP PP 1.2 (8.3, 15.3) 5.3 (4.3, 6.7).42 (.28,.63).8.6 Atezolizumab + PP (n=221) PP (n=221).8.6 Atezolizumab + PP (n=71) PP (n=65) Time, months Median PFS (95%CI), mos HR (95%CI) Former/current smokers Atezolizumab + PP PP 7.5 (6.3, 8.4) 5.1 (4.3, 5.6).61 (.5,.74) Time, months Median PFS (95%CI), mos HR (95%CI) Never smokers Atezolizumab + PP PP 8.6 (6.5, 15.4) 5.5 (4., 8.3).49 (.28,.87).8.6 Atezolizumab + PP (n=225) PP (n=226).8.6 Atezolizumab + PP (n=37) PP (n=3) Time, months Time, months Conclusion Atezolizumab added to carboplatin/cisplatin + pemetrexed improved PFS across several subgroups including patients from Asia, never smokers, those who were older and those without liver metastases at baseline, but currently has not shown improvement in OS Barlesi F, et al. Ann Oncol 218;29(suppl 5):Abstr LBA54
36 LBA55: Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (btmb) as a predictive biomarker for atezolizumab (atezo) in 1L nonsmall cell lung cancer (NSCLC) Kim ES, et al Study objective To investigate the use of btmb as a predictive biomarker for atezolizumab monotherapy in 1L NSCLC Key patient inclusion criteria Stage IIIB/IVA locally advanced or metastatic NSCLC Immunotherapy naïve PD-L1 unselected ECOG PS 1 (n=152) Atezolizumab 12 mg q3w (biomarker evaluable population n=119) PD/toxicity/ loss of benefit Co-primary endpoints Investigator-assessed ORR and PFS (using pre-specified btmb cut-off of 16) Secondary endpoints Safety, investigator-assessed DoR and OS Kim ES, et al. Ann Oncol 218;29(suppl 5):Abstr LBA55
37 Overall response rate, % LBA55: Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (btmb) as a predictive biomarker for atezolizumab (atezo) in 1L nonsmall cell lung cancer (NSCLC) Kim ES, et al Key results ORR per RECIST v1.1 btmb subgroups 1 cut-off 16 cut-off 2 cut-off p<.1 4 PR CR p= % 35 3 p= % % 1.1% 16.3% 5.7% 4.4% 5% ITT (N=152) BEP (n=119) High (n=49) Low (n=7) High (n=28) Low (n=91) High (n=19) Low (n=1) Kim ES, et al. Ann Oncol 218;29(suppl 5):Abstr LBA55
38 LBA55: Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (btmb) as a predictive biomarker for atezolizumab (atezo) in 1L nonsmall cell lung cancer (NSCLC) Kim ES, et al Progression-free survival, % Key results (cont.) PFS in btmb high ( 16) vs. low (<16) subgroups 1 8 High, 16 (n=28) Low, <16 (n=91) Median PFS, months (9%CI) btmb high (n=28) btmb low (n=91) 4.6 (1.6, 11.) 3.7 (2.6, 4.3) 6 6-month PFS 41.6% vs. 32.8% HR (9%CI).66 (.42, 1.2) p-value month PFS 37.4% vs. 9.7% No. at risk High ( 16) Low (<16) Conclusion Time, months In patients with NSCLC treated with atezolizumab monotherapy a numerical improvement in outcomes was seen in those with a btmb cut-off of Kim ES, et al. Ann Oncol 218;29(suppl 5):Abstr LBA55
39 LBA58: Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial Popat S, et al Study objective To investigate the intracranial efficacy of brigatinib vs. crizotinib in ALK inhibitornaïve patients with advanced ALK+ NSCLC in the ATLA-1L study Key patient inclusion criteria Stage IIIb/IV NSCLC ALK+ (based on local ALK testing) No prior ALK inhibitor 1 prior systemic therapy R 1:1 Brigatinib 18 mg/day (9 mg/day for 7 day lead-in) (n=137) Stratification Brain metastases at baseline Prior chemotherapy PD/toxicity/ discontinuation Brain metastases were allowed (n=275) Crizotinib 25 mg bid (n=138) PD*/toxicity/ discontinuation Primary endpoint PFS (BIRC-assessed) Secondary endpoints ORR, intracranial ORR, intracranial PFS, OS, safety *Crossover to brigatinib permitted at PD Popat S, et al. Ann Oncol 218;29(suppl 5):Abstr LBA58
40 PFS, % of patients PFS, % of patients LBA58: Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial Popat S, et al Key results Whole body BIRC-assessed PFS by brain metastases at baseline 1 8 With brain metastases HR.2 (95%CI.9,.46) p<.1 by log-rank test 1 8 Without brain metastases HR.72 (95%CI.44, 1.18) p=.2 by log-rank test Brigatinib (n=4) Crizotinib (n=41) Time, months 2 Brigatinib (n=97) Crizotinib (n=97) Time, months Treatment Pts with events, n (%) Median PFS, months (95%CI) 1-year PFS rate, % (95%CI) Brigatinib (n=4) 8 (2) NR 75 (56, 87) Crizotinib (n=41) 24 (59) 5.6 (3.8, 11.1) 25 (8, 46) Treatment Pts with events, n (%) Median PFS, months (95%CI) 1-year PFS rate, % (95%CI) Brigatinib (n=97) 28 (29) NR 63 (5, 74) Crizotinib (n=41) 39 (4) 11.1 (9.2, NR) 49 (36, 61) Conclusion In patients with advanced ALK+ NSCLC, brigatinib demonstrated superior intracranial efficacy vs. crizotinib, with significantly higher intracranial response and improved intracranial PFS in those with brain metastases Popat S, et al. Ann Oncol 218;29(suppl 5):Abstr LBA58
41 1377O: Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small lung cancer (NSCLC) Wu Y, et al Study objective To investigate the efficacy and safety of tepotinib + gefitinib vs. chemotherapy in Asian patients with advanced MET+/EGFR+T79M- NSCLC Key patient inclusion criteria Locally-advanced/metastatic IV NSCLC EGFR+, T79M, MET+ Asian Resistance to prior EGFR TKI No prior HGF/MET pathwaydirected therapy (n=55) Primary endpoint PFS (investigator-assessed) R* Tepotinib 5 mg/day + gefitinib 25 mg/day (n=31) Stratification Secondary endpoints ORR, safety PD/ toxicity MET+ type (IHC2+, IHC3+ or MET amplification) Prior EGFR-TKI therapy Chemotherapy: Pemetrexed 5 mg/m 2 q3w+ cisplatin 75 mg/m 2 or carboplatin AUC 5 or 6 q3w (n=24) PD/ toxicity *Initially 1:1 and changed to 2:1 at protocol amendment (3 Sept 216) Wu Y, et al. Ann Oncol 218;29(suppl 5):Abstr 1377O
42 KM estimate for PFS 1377O: Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small lung cancer (NSCLC) Wu Y, et al Key results Investigator-assessed PFS (ITT population) Tepotinib + gefitinib (n=31) Chemotherapy (n=24) Events Median PFS, months (9%CI) 4.9 (3.9, (4.2, 6.8) Stratified HR (9%CI).71 (.36, 1.39) Tepotinib + gefitinib Chemotherapy No. at risk Tep + gef Chemo Time, months In the MET IHC3+ subgroup (n=34) median PFS was 8.3 months with tepotinib + gefitinib and 4.4 months with chemotherapy (HR.35 [95%CI.17,.74]) In the MET amplification subgroup (n=19) median PFS was 21.2 months with tepotinib + gefitinib and 4.2 months with chemotherapy (HR.17 [95%CI.5,.57]) Wu Y, et al. Ann Oncol 218;29(suppl 5):Abstr 1377O
43 1377O: Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small lung cancer (NSCLC) Wu Y, et al Key results Responders* n/n Overall (n=55) 14/31 MET IHC3+ (n=34) 13/19 MET amplification (n=19) 8/12 Tepotinib + gefitinib ORR, % (9%CI) 45.2 (29.7, 61.3) 68.4 (47., 85.3) 66.7 (39.1, 87.7) Responders* n/n 8/24 5/15 3/7 Chemotherapy ORR, % (9%CI) 33.3 (17.8, 52.1) 33.3 (14.2, 57.7) 42.9 (12.9, 77.5) Odds ratio (9%CI) 1.99 (.56, 6.87) 4.33 (1.3, 18.33) 2.67 (.37, 19.56) Tepotinib + gefitinib was generally well tolerated, with TEAEs leading to discontinuation in 9.7% of patients compared with 4.3% in the chemotherapy group Conclusion In patients with advanced NSCLC and MET amplifications, improvements in PFS were observed with tepotinib + gefitinib, indicating that MET may be considered as a biomarker for treatment with tepotinib *No confirmation required Wu Y, et al. Ann Oncol 218;29(suppl 5):Abstr 1377O
44 1379PD: Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (ansclc) in the global phase III ALEX study Dziadziuszko R, et al Study objective To assess efficacy of alectinib vs. crizotinib in the ALEX trial in patients with ALK+ advanced NSCLC stratified by EML4-ALK fusion variants Key patient inclusion criteria ALK+ NSCLC No prior treatment for NSCLC ECOG PS 2 (n=33) R 1:1 Alectinib 6 mg bid Crizotinib 25 mg bid PD/death/ withdrawal PD/death/ withdrawal Methods FOUNDATIONACT and FOUNDATIONONE NGS platforms were used to determine the ALK fusion variants in plasma and tissue BEP subgroups Dziadziuszko R, et al. Ann Oncol 218;29(suppl 5):Abstr 1379PD
45 Survival probability 1379PD: Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (ansclc) in the global phase III ALEX study Dziadziuszko R, et al Key results PFS (investigator-assessed) Plasma BEP subgroup Tissue BEP subgroup 1. Crizotinib Median PFS, months EML4-ALK V1: 7.4 EML4-ALK V2: 8.8 EML4-ALK V3a/b: Alectinib Median PFS, months EML4-ALK V1: NE EML4-ALK V2: 14.9 EML4-ALK V3a/b: NE 1. Crizotinib Median PFS, months EML4-ALK V1: 12.9 EML4-ALK V2: 8.8 EML4-ALK V3a/b: Alectinib Median PFS, months EML4-ALK V1: NE EML4-ALK V2: 11.5 EML4-ALK V3a/b: NE Time, months Time, months Time, months Time, months ALK V1 ALK V2 ALK V3a/b Conclusion In patients with ALK+ NSCLC alectinib demonstrated greater efficacy than crizotinib, regardless of EML4-ALK variant Dziadziuszko R, et al. Ann Oncol 218;29(suppl 5):Abstr 1379PD
46 138PD: Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations Solomon BJ, et al Study objective To investigate molecular profiling of patients with ROS1+ advanced NSCLC in the B74611 study of lorlatinib Methods Patients with locally advanced or metastatic NSCLC with ROS1 rearrangements were enrolled in the phase 1/2 study Patients were treatment-naïve in the advanced setting of PD after 1 prior ROS1 inhibitor (phase 1) or any number of prior therapies (phase 2) Lorlatinib was orally administered in continuous 21-day cycles with escalating doses (1 mg/day to 1 mg bid) in phase 1 and 1 mg/day in phase 2 Molecular profiling of tumour tissue and blood was performed All patients had tissue samples collected before enrolment and tissue collection was encouraged on PD; tumour tissue was analysed with a ROS1 kinase domain mutationfocused NGS panel Blood samples were collected at screening, at the beginning of cycle 3, and at the endof-treatment visit for circulating-free DNA (cfdna) analysis using an NGS panel or digital PCR Solomon BJ, et al. Ann Oncol 218;29(suppl 5):Abstr 138PD
47 Best percentage change from baseline 138PD: Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations Solomon BJ, et al Key results ORR by presence of ROS1 mutations ROS1 TKI-naïve (n=17) No mutation (n=17) Best overall response, n (%) 1 mutation (n=) Prior crizotinib (n=36)* No mutation (n=27) 1 mutation (n=8) Prior noncrizotinib TKI or 2 TKIs (n=5) No mutation (n=4) 1 mutation (n=1) CR 2 (11.8) 1 (3.7) Percentage change in tumour size from baseline in patients with 1 ROS1 kinase domain mutation Best overall response Partial response Stable disease Progressive disease PR 9 (52.9) 8 (29.6) 2 ( 25.) SD 5 (29.4) 8 (29.6) 5 (62.5) 3 (75.) 1 (1) PD 1 (5.9) 3 (11.1) 1 (12.5) 1 (25.) Indeterminate 7 (25.9) Responders, n (%) 11 (64.7) 9 (33.3) 2 (25.) *One patient had a non-analysable or uninformative sample ROS1 kinase domain mutation in: cfdna Tumour tissue Both cfdna and tumour tissue Conclusions ROS1 kinase domain mutations occurred in 1 14% of samples In patients with ROS1 kinase domain resistance mutations, lorlatinib exhibited some anti-tumour activity Solomon BJ, et al. Ann Oncol 218;29(suppl 5):Abstr 138PD
48 1381PD Gefitinib with or without pemetrexed in nonsquamous non-small cell lung cancer with EGFR mutation: Final overall survival results from a randomized phase II study Chih-Hsin Yang J, et al Study objective To investigate the efficacy and safety of pemetrexed + gefitinib vs. gefitinib in non-squamous NSCLC with EGFR mutations Key patient inclusion criteria Stage IV or recurrent non-squamous NSCLC Activating EGFR mutations East Asian 18 years ( 2 years in Japan and Taiwan) No prior systemic therapy for stage IV or recurrent NSCLC ECOG PS 1 (n=191) R 2:1 Pemetrexed 5 mg/m 2 q3w + gefitinib 25 mg/day (n=126) Gefitinib 25 mg/day (n=65) Primary endpoint PFS Secondary endpoints OS, time to progressive disease, tumour response rates, DoR, QoL, biomarker analysis, safety Chih-Hsin Yang J et al. Ann Oncol 218;29(suppl 5):abstr 1381PD
49 Probability Probability 1381PD Gefitinib with or without pemetrexed in nonsquamous non-small cell lung cancer with EGFR mutation: Final overall survival results from a randomized phase II study Chih-Hsin Yang J, et al Key results OS Median OS, months (95%CI) Pemetrexed + gefitinib 43.4 months (33.4, 5.8) Gefitinib 36.8 months (26.7, 42.6) Adjusted HR.77 (95%CI.5, 1.2) 1-sided p= Updated PFS Median PFS, months (95%CI) Pemetrexed + gefitinib 16.2 months (12.6, 18.7) Gefitinib 11.1 months (9.7, 13.8) Adjusted HR.67 (95%CI.5,.9) 1-sided p= No.at risk P+G G Time, months No.at risk P+G G Time, months (28.6%) patients had TEAEs in the pemetrexed + gefitinib group and 7 (1.8%) in gefitinib group Conclusion In patients with EGFR+ advanced NSCLC pemetrexed + gefitinib significantly prolonged PFS, with a numerically longer, but not statistically significant, improvement in OS Chih-Hsin Yang J et al. Ann Oncol 218;29(suppl 5):abstr 1381PD
50 1382PD: Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as 1st-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ9) Seike M, et al Study objective To investigate the efficacy and safety of gefitinib + carboplatin + pemetrexed vs. gefitinib in patients with non-squamous NSCLC Induction phase Maintenance phase Key patient inclusion criteria Treatment naïve patients with non-squamous IIIB/IV NSCLC EGFR+ R 1:1 Gefitinib 25 mg/day + carboplatin AUC6 + pemetrexed 5 mg/m 2 Stratification Sex EGFR mutation Smoking history Gefitinib + pemetrexed q3w PS 1 (n=345) Gefitinib 25 mg/day Platinumbased regimen Primary endpoints Secondary endpoints PFS, PFS2, OS ORR, safety, QoL Seike M, et al. Ann Oncol 218;29(suppl 5):Abstr 1382PD
51 Progression-free survival, % Overall survival, % 1382PD: Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as 1st-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ9) Seike M, et al Results PFS Updated OS No. at risk Gefitinib Gef + carb + pem Time, months No. at risk Gefitinib Gef + carb + pem Time, months Gefitinib Gefitinib + carb + pem Median PFS, months (95%CI) 11.2 (9., 13.4) 2.9 (18., 24.) HR (95%CI); p-value.49 (.388,.62); <.1 Gefitinib Gefitinib + carb + pem mos, months (95% CI) 38.8 (31.1, 47.3) 5.9 (41.8, 62.5) HR (95%CI); p-value.72 (.58,.95);.2 Conclusions PFS and OS were significantly improved in patients treated with combination therapy of gefitinib + carboplatin + pemetrexed There was no difference in PFS2 Seike M, et al. Ann Oncol 218;29(suppl 5):Abstr 1382PD
52 1385PD: A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC the ETOP and EORTC SPLENDOUR trial Peters S, et al Study objective To investigate the efficacy of denosumab as an add-on to standard 1L doublet chemotherapy + BSC in patients with NSCLC in the SPLENDOUR study Denosumab 12 mg every 3 4 weeks + chemotherapy (4 6 cycles) (n=255) Key patient inclusion criteria Stage IV NSCLC (n=514) R 1:1 Stratification Bone metastases PS Histology Region Chemotherapy (4 6 cycles) + BSC* (n=259) Primary endpoint OS Secondary endpoints PFS, OS by bone metastases, safety *Zoledronic acid in case of skeletal involvement Peters S, et al. Ann Oncol 218;29(suppl 5):Abstr 1385PD
53 OS, % PFS, % 1385PD: A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC the ETOP and EORTC SPLENDOUR trial Peters S, et al Key results OS PFS 1 8 Denosumab BSC 1 8 Denosumab BSC No. at risk Denosumab BSC Years No. at risk Denosumab BSC Months Treatment Events/ patients Denosumab 177/258 BSC 178/255 Non-parametric Median, years (95%CI).68 (.62,.87).73 (.63,.92) 1 year, % (95%CI) 4.2 (33.8, 46.5) 4.2 (33.8, 46.5) HR (95%CI).96 (.78, 1.18) Cox model p-value (Score test) Treatment Events/ patient Denosumab 228/259 BSC 227/254 Non-parametric Median, years (95%CI).39 (.35,.44).39 (.34,.44) 1 year, % (95%CI) 13.1 (9.1, 17.9) 9.3 (6., 13.6) HR (95%CI).97 (.81, 1.17) Cox model p-value (Score test) Peters S, et al. Ann Oncol 218;29(suppl 5):Abstr 1385PD
54 OS, % OS, % 1385PD: A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC the ETOP and EORTC SPLENDOUR trial Peters S, et al Key results (cont.) 1 8 OS Bone metastases Denosumab BSC 1 8 OS No bone metastases Denosumab BSC No. at risk Denosumab BSC N Months Months No. at risk Denosumab BSC N Treatment Events/ patients Denosumab 98/138 BSC 98/137 Non-parametric Median, years (95%CI).62 (.46,.73).61 (.51,.82) 1 year, % (95%CI) 34.4 (26.1, 43.) 35.8 (27.5, 44.2) HR (95%CI) 1.3 (.78, 1.37) Cox model p value (Score test) Treatment Events/ patients Denosumab 79/121 BSC 8/118 Non-parametric Median (years) (95%CI).89 (.67, 1.35).92 (.71, 1.5) 1 year, % (95%CI) 46.9 (37.2, 55.9) 45.4 (35.7, 54.6) Hazard Ratio (95%CI).89 (.65, 1.22) Cox model P-Value (Score test) Conclusions Denosumab added to 1L platinum-based chemotherapy did not improve OS There were no safety concerns with denosumab Peters S, et al. Ann Oncol 218;29(suppl 5):Abstr 1385PD
55 Advanced NSCLC Not radically treatable stage III and stage IV Later lines
56 LBA63: Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-1 study overall and in pts who completed 2 years of pembrolizumab (pembro) Herbst RS, et al Study objective Long-term follow-up of KEYNOTE-1 investigating pembrolizumab vs. docetaxel in patients with advanced NSCLC and PD-L1 TPS 1% who had progressed after platinum-containing chemotherapy Key patient inclusion criteria Advanced NSCLC PD-L1 TPS 1% Progression after 1 line of chemotherapy No active brain metastases Endpoints in TPS 5% and 1% populations OS, PFS ORR, DoR, safety R 1:1:1 Pembrolizumab 2 mg/kg q3w for 24 months Pembrolizumab 1 mg/kg q3w for 24 months Docetaxel 75 mg/m 2 q3w Stratification ECOG PS ( vs. 1) Region (East Asia vs. non-east Asia) PD-L1 status (TPS 5% vs. 1 49%) Herbst RS, et al. Ann Oncol 218;29(suppl 5):Abstr LBA63
57 Overall survival, % Overall survival, % LBA63: Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-1 study overall and in pts who completed 2 years of pembrolizumab (pembro) Herbst RS, et al Key results PD-L1 TPS 5% population OS PD-L1 TPS 1% population N Events, n (%) Median OS, mo (95%CI) HR (95%CI); p-value N Events, n (%) Median OS, mo (95%CI) HR (95%CI); p-value Pembrolizumab (69) 16.9 (12.3, 21.4) Docetaxel (84) 8.2 (6.4, 9.8).53 (.42,.66); <.1 Pembrolizumab (79) 11.8 (1.4, 13.1) Docetaxel (86) 8.4 (7.6, 9.5).69 (.6,.8); < % 13% % 11% No. at risk Pembro Docetaxel Time, months No. at risk Pembro Docetaxel Time, months Herbst RS, et al. Ann Oncol 218;29(suppl 5):Abstr LBA63
58 LBA63: Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-1 study overall and in pts who completed 2 years of pembrolizumab (pembro) Herbst RS, et al Key results (cont.) Overall, median treatment duration was 3.5 months (range ) in the pembrolizumab group (n=682) and 2. months (range ) in the docetaxel group (n=39) 79 patients completed 35 cycles or 2 years of pembrolizumab with a median follow-up of 43.4 months (range ) 75/79 (95%) patients had a CR or PR 48/75 (64%) patients had ongoing response, median DoR NR (range months) Median OS was NR (95%CI NR, NR) The Kaplan-Meier estimate of 36-month OS rate was 98.7% (95%CI 91.2, 99.8) 25/79 (32%) patients had PD after stopping 35 cycles or 2 years of pembrolizumab In 14 patients who received a second course of pembrolizumab after 35 cycles or 2 years of treatment and subsequent PD, 6 (43%) had PR and 5 (36%) had SD Conclusions In patients with PD-L1-expressing advanced NSCLC, pembrolizumab continued to prolong OS compared with docetaxel In patients who completed 2 years of pembrolizumab AEs were manageable and responses were durable Herbst RS, et al. Ann Oncol 218;29(suppl 5):Abstr LBA63
59 1378O: ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in 3L advanced NSCLC treatment Kowalski DM, et al Study objective To investigate the efficacy and safety of durvalumab vs. SoC and the combination of durvalumab + tremelimumab vs. SoC in subgroups based on PD-L1 expression ( 25% or <25%) in the ARCTIC study Key patient inclusion criteria Stage IIIB/IV NSCLC 2 prior treatments Immunotherapy-naïve Stratification Planned SoC, histology Study A PD-L1 TC 25% (n=126) Study B EGFR/ALK wild-type PD-L1 TC WHO PS /1 <25% SoC* (n=469) Primary endpoint OS, PFS (investigator assessed R Durvalumab 1 mg/kg q2w for up to 12 mo (n=62) 1:1 SoC* (n=64) R 3:2:2:1 Durvalumab 2 mg/kg + tremelimumab 1 mg/kg q4w for 12 weeks then durvalumab 1 mg/kg for 34 weeks (n=174) (n=118) Durvalumab 1 mg/kg q2w for up to 12 mo (n=117) Tremelimumab 1 mg/kg q4w for 24 weeks then q12w for 24 weeks (n=6) Secondary endpoints 1-year OS and PFS rates, ORR, safety *Erlotinib, gemcitabine, or vinorelbine Kowalski DM, et al. Ann Oncol 218;29(suppl 5):Abstr 1378O
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationIASLC 19th World Conference on Lung Cancer
Developed in association with the European Thoracic Oncology Platform IASLC 19th World Conference on Lung Cancer September 23 26 218 Toronto, Canada Supported by Eli Lilly and Company. Eli Lilly and Company
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationIASLC 17th World Conference on Lung Cancer
Developed in association with the European Thoracic Oncology Platform IASLC 17th World Conference on Lung Cancer December 4 7, 2016 Vienna, Austria Supported by Eli Lilly and Company. Eli Lilly and Company
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationUpdates in Lung Cancer
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationUpdates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationmemo inoncology SPECIAL ISSUE
Springer-Verlag 2018 www.memoinoncology.com 03/18 www.memoinoncology.com memo inoncology SPECIAL ISSUE Congress Report A GLOBAL CONGRESS DIGEST ON LUNG CANCER Report from the European Society for Medical
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationIASLC 18th World Conference on Lung Cancer
Developed in association with the European Thoracic Oncology Platform IASLC 18th World Conference on Lung Cancer October 15 18, 2017 Yokohama, Japan Supported by Eli Lilly and Company. Eli Lilly and Company
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationSummary THORACIC MALIGNANCIES NSCLC, Metastatic... 4
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 3 THORACIC MALIGNANCIES NSCLC, Metastatic... 4 PD-1 inhibition shows promise as first-line treatment in high PD-L1
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More information3/13/2018. Case 1. Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board
Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board Matthew Gubens, MD MS, UC San Francisco, Chair Julia Rotow, MD, UC San Francisco, Fellow Colin Blakely, MD PhD, UC San Francisco GigI
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More information